Researchers Achieve a Significant Advancement in Early Diagnosis of Bipolar Disorder in Adolescents

In a groundbreaking study S’ouvre dans une nouvelle fenêtre in Biological Psychiatry S’ouvre dans une nouvelle fenêtre, published by Elsevier, researchers report significant strides in enhancing early diagnosis of bipolar disorder in adolescents. They demonstrate the efficacy of integrating multimodal MRI with behavioral assessments for greater diagnostic precision. Bipolar disorder is a severe neuropsychiatric condition that often emerges during adolescence and is characterized by extreme mood swings.

This research, led by Kangguang Lin, MD, PhD, Department of Affective Disorders, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Medical University, and Jie Wang, PhD, Songjiang Research Institute, Songjiang Hospital, Shanghai Jiao Tong University School of Medicine, could change how we identify young people at risk for bipolar disorder. They aimed to improve the early detection and treatment of this condition, which is crucial for helping young patients in over time.

Dr. Wang explains, “The integration of behavioral and neuroimaging data has the potential to transform the field of neuropsychiatric diagnosis, particularly for conditions like bipolar disorder where early detection is crucial. This approach could lead to earlier interventions, potentially improving outcomes for affected individuals.”

The team used advanced brain imaging techniques to study adolescents who are at risk for bipolar disorder. A group of 309 subjects, including bipolar disorder patients, offspring of bipolar disorder patients (with and without subthreshold symptoms), non-bipolar disorder offspring with subthreshold symptoms, and healthy controls, was analyzed. Behavioral attributes were integrated with multimodal MRI features. Three diagnostic models were developed: a clinical diagnosis model based on behavioral attributes, an MRI-based model, and a comprehensive model integrating both datasets.

Their key finding was that combining various neuroimaging modalities can reveal specific changes in brain networks that signal early-stage bipolar disorder. This approach not only helps diagnose the disorder more accurately, but also offers valuable insights into its biological causes, potentially leading to better and more personalized treatments.

Dr. Lin notes, “Given the challenges in diagnosing bipolar disorder in adolescents, our findings mark a major advance in early detection. By combining various imaging techniques, we can now identify at-risk young people with remarkable accuracy.”

Commenting on the significance of the study, John Krystal, MD, Editor of Biological Psychiatry, says, “We have long expected that brain imaging would help to improve the psychiatric diagnostic process. Here we have a very promising example where the information gained from several forms of MRI, combined with clinical information, improve upon the accuracy of traditional clinical diagnosis.”

Dr. Krystal continues, “When people think about MRI, they often imagine that a radiologist is looking for gross abnormalities that might be easily visible when the MRI is presented on a screen. However, in this case, very detailed automated MRI analyses are conducted that might pick up structural differences that might not be apparent otherwise. Further, this study employed two other forms of MRI imaging, resting state functional MRI (rsFMRI) and diffusion tensor imaging (DTI). rsFMRI analyzes the pattern of communication between brain regions, i.e., their correlated activity. DTI measures the structural integrity of neural pathways by measuring the movement of water within and around the neural pathways in the brain.”

These findings encourage further exploration into advanced imaging in psychiatry, with implications for improving patient outcomes.

Notes for editors

The article is "Enhancing Early Diagnosis of Bipolar Disorder in Adolescents through Multimodal Neuroimaging,” by Jinfeng Wu, PhD, Kangguang Lin, MD, PhD, Weicong Lu, MD, Wenjin Zou, MD, Xiaoyue Li, MD, Yarong Tan, MD, Jingyu Yang, PhD, Danhao Zheng, PhD, Xiaodong Liu, PhD, Bess Yin-Hung Lam, PhD, Guiyun Xu, MD, Kun Wang, Roger S. McIntyre, MD, Fei Wang, PhD, Kwok-Fai So, PhD, and Jie Wang, PhD (https://doi.org/10.1016/j.biopsych.2024.07.018 S’ouvre dans une nouvelle fenêtre). It appears online in Biological Psychiatry, published by Elsevier.

The article is openly available for 30 days at https://www.biologicalpsychiatryjournal.com/article/S0006-3223(24)01485-9/fulltext S’ouvre dans une nouvelle fenêtre.

Copies of this paper and additional information are also available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected] S’ouvre dans une nouvelle fenêtre. Journalists wishing to interview the authors should contact Kangguang Lin, MD, PhD, at:+86 135 6036 0144, [email protected] S’ouvre dans une nouvelle fenêtre, or Jie Wang, PhD, at +86 18627952376 [email protected] S’ouvre dans une nouvelle fenêtre.

This project was supported by grants from the National Natural Science Foundation of China and the Science and Technology Program of Guangzhou, China. The authors also acknowledge the contributions of all team members and external collaborators.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here S’ouvre dans une nouvelle fenêtre.

About Biological Psychiatry

Biological Psychiatry S’ouvre dans une nouvelle fenêtre is the official journal of the Society of Biological Psychiatry S’ouvre dans une nouvelle fenêtre, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th^th out of 279 Psychiatry titles and 15^th out of 309 Neurosciences titles in Journal Citation Reports^TM published by Clarivate. The 2023 Impact Factor score for Biological Psychiatry is 9.6.www.sobp.org/journal S’ouvre dans une nouvelle fenêtre

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation S’ouvre dans une nouvelle fenêtre, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX S’ouvre dans une nouvelle fenêtre, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.